HUTCHMED (China) Ltd
HKEX:13
HUTCHMED (China) Ltd
Total Equity
HUTCHMED (China) Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Total Equity
$740.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Total Equity
HK$16.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
31%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Total Equity
¥14.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
17%
|
CAGR 10-Years
10%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Total Equity
¥32B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
20%
|
|
|
C
|
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
|
Total Equity
¥21.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
21%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Total Equity
HK$48.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
HUTCHMED (China) Ltd
Glance View
HUTCHMED (China) Ltd., a hybrid of innovation and tradition, stands at the intersection of global pharmaceutical ambitions and Chinese herbal expertise. Born out of a joint venture between Hutchison Whampoa and Chi-Med, the company has steadily carved out a niche by developing a dual-pronged business model that merges cutting-edge biotechnology with traditional Chinese medicine. This hybrid approach enables HUTCHMED to leverage the best of both worlds by combining the rich pharmacological heritage of China with modern scientific research. Its pipeline includes a range of drugs aimed at treating various cancers and immunological disorders, developed through deep-pocketed collaborations and alliances with multinational corporations. Revenue streams at HUTCHMED primarily flow from drug discoveries and developments that pass through rigorous clinical trials, reaching commercialization both in China and internationally. The company invests significantly in R&D to advance its pipeline, while also generating income through strategic partnerships that involve licensing agreements and joint ventures. This allows HUTCHMED not only to mitigate risks associated with drug development but also to tap into diverse markets by navigating a multifaceted regulatory landscape. By paving the way for western pharmaceutical technologies alongside traditional medicinal insights, HUTCHMED creates a sustainable growth trajectory in an ever-evolving global healthcare market.
See Also
What is HUTCHMED (China) Ltd's Total Equity?
Total Equity
740.1m
USD
Based on the financial report for Dec 31, 2024, HUTCHMED (China) Ltd's Total Equity amounts to 740.1m USD.
What is HUTCHMED (China) Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
34%
Over the last year, the Total Equity growth was -5%. The average annual Total Equity growth rates for HUTCHMED (China) Ltd have been -9% over the past three years , 21% over the past five years , and 34% over the past ten years .
You don't have any saved screeners yet